Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma

Research output: Contribution to journalArticle

Abstract

Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on historso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.

Original languageEnglish (US)
Article number6
JournalDermatology online journal
Volume25
Issue number2
StatePublished - Jan 1 2019

Fingerprint

Carcinoma
Skin
Immunoglobulin Isotypes
Dermatitis
Drug Delivery Systems
Exanthema
Keratinocytes
Adrenal Cortex Hormones
Therapeutics
Extremities
Antibodies
Pharmaceutical Preparations
nectins

Keywords

  • Adverse drug reaction
  • Drug rash

ASJC Scopus subject areas

  • Dermatology

Cite this

Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. / Wu, Sam; Adamson, Adewole.

In: Dermatology online journal, Vol. 25, No. 2, 6, 01.01.2019.

Research output: Contribution to journalArticle

@article{cf38ea762f7e4d82b3e41bb63e452c78,
title = "Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma",
abstract = "Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on historso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.",
keywords = "Adverse drug reaction, Drug rash",
author = "Sam Wu and Adewole Adamson",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "25",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "2",

}

TY - JOUR

T1 - Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma

AU - Wu, Sam

AU - Adamson, Adewole

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on historso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.

AB - Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on historso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.

KW - Adverse drug reaction

KW - Drug rash

UR - http://www.scopus.com/inward/record.url?scp=85062848335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062848335&partnerID=8YFLogxK

M3 - Article

C2 - 30865407

AN - SCOPUS:85062848335

VL - 25

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 2

M1 - 6

ER -